Probiotic dairy could help block HIV

By Chris Mercer

- Last updated on GMT

Scientists have devised a way of using 'live' bacteria in yoghurt
to deliver medicine that can prevent HIV infection, potentially
opening up a new avenue for probiotic dairy development.

The researchers, from both the US and Europe, say they managed to genetically modify the Lactococcus lactis bacteria so that it produces cyanovirin - a drug that has blocked HIV infection during tests on monkeys and is set for human trials next year.

L. lactis produces lactic acid and so is used widely to make cheese and yoghurt. Some probiotic dairy products, mainly yoghurts, that claim to benefit gut health also contain different strains of the bacteria.

Bharat Ramratnam, one of the researchers and an HIV expert at Brown Medical School, told DairyReporter.com​ it was possible that probiotic food products could be made containing cyanovirin.

However, the team only focused on how to block the sexual transmission of HIV, which means that the live bacteria would have to be capable of moving from the gut down to the vagina.

L. lactis is already found naturally in both the human gut and vaginal wall, suggesting that any strain introduced would have a good chance of survival.

And, Ramratnam said there was also evidence the bacteria could move from one to the other, but: "there are hundreds of strains and not much is known about any of these. All of this depends on choosing the right strain."

The researchers emphasised that, even if HIV-blocking foods were a little way off, L. lactis containing cyanovirin may still be manufactured as a drug.

Either method could be a much cheaper way of combatting the fast-spreading HIV virus. The World Health Organistion estimated that 40m adults and children were living with HIV in 2005, with 4.9m new infections during the year.

Ramratnam said the team first needed to test and perfect their use of L. lactis as a delivery vehicle for cyanovirin.

He said the researchers needed to look at whether the L. lactis would still work in the same way after being genetically modified. Secondly, if it does, they must assess whether the bacteria will send out enough of the cyanovirin compound to halt HIV infection.

Lastly, but not least, Ramratnam said the team needed to be sure that cyanovirin was safe. "No one has ever applied this to animals for months at a time,"​ he said, adding the testing may not be complete for two or three years.

Initial tests have shown that cyanovirin blocks a receptor the HIV uses to infect cells by binding itself to sugar molecules attached to the HIV virus.

Even if things do not work out as planned, however, Ramratnam said the team had still shown that L. lactis "can be used as a vehicle for drug delivery"​.

This, he said, meant that strains of so-called 'friendly bacteria' could be used as transport in the fight against certain other infectious diseases. "There are a lot of molecules with anti-viral properties, but there is currently no way of delivering them to the human body."

Related topics Ingredients

Related news

Related products

show more

Bun quality issues? Let us help

Bun quality issues? Let us help

Content provided by Corbion | 03-Jan-2024 | Insight Guide

Most bakeries occasionally struggle with bun quality, from low product volume to crust issues and grain/cell problems. The good news is that most bun quality...

Plant-based prowess

Plant-based prowess

Content provided by ADM: Innovation that Feeds the Future | 18-Oct-2023 | Case Study

Today, a unique challenge faces food producers. As plant-based awareness grows, consumers are becoming more conscientious of what they eat and how it fuels...

Tomorrow’s bakery shortenings. Today.

Tomorrow’s bakery shortenings. Today.

Content provided by Cargill Oils | 10-Oct-2023 | White Paper

“The Next Generation of Bakery Shortenings” addresses the challenges of today’s functional issues and consumer taste preferences. To say bakery fats are...